{ "article_id": 1409, "public_id": "334df2c2-3963-4535-8a95-80bb872254d5", "internal_identifier": null, "source_identifier": "87:76", "status": "published", "type": "research_article", "title": "Heparinin İndüklediği Trombositopeni: Olgu sunumu", "title_secondary": null, "abstract": "Heparinin indüklediği trombositopeni (HİT), heparin kullanımı sonrası immünolojik mekanizmalar yoluyla gelişen, arteriyel ve venöz tromboembolizm ile karakterize katastrofik  nadir görülen bir komplikasyondur. heparin kullanımını takiben genellikle 5-14. günlerde gelişir. HİT geliştiğinde heparin tedavisi kesilmeli ve direkt trombin inhibitörleri başlanmalıdır.Bu yazıda HİT’ye bağlı tromboembolik komplikasyonlar gelişen bir olgu sunarak nadir görülen bu komplikasyona farkındalık oluşturmayı amaçladık.", "language": "tr", "english_title": "Heparin-Induced Thrombocytopenia: Case Report", "english_abstract": "Heparin-induced thrombocytopenia (HIT) is a catastrophic, rare complication characterized by arterial and venous thromboembolism that develops via immunological mechanisms following heparin use. It usually develops 5-14 days after heparin administration. When HIT develops, heparin treatment should be discontinued and direct thrombin inhibitors should be initiated. In this article, we aim to raise awareness of this rare complication by presenting a case of thromboembolic complications that developed due to HIT.", "doi": "10.36287/setsci.4.9.076", "doi_url": "https://doi.org/10.36287/setsci.4.9.076", "resource_url": "https://www.set-science.com/a/334df2c2-3963-4535-8a95-80bb872254d5", "pdf_url": "https://www.set-science.com/a/334df2c2-3963-4535-8a95-80bb872254d5/pdf", "og_image": "https://www.set-science.com/assets/img/og-card-v2.png", "authors": [ { "public_id": "38b6d50d-eeea-4f84-a81a-9177dc526fac", "given": "Alperen", "family": "Kısa", "full": "Alperen Kısa", "literal": null, "orcid": null, "orcid_url": null, "email": "alperenkisa@hotmail.com.tr", "corresponding": true, "sequence": "first", "affiliations": [ { "name": "Hitit University", "department": null, "country": null, "country_code": null, "ror": null, "ror_url": null } ] } ], "keywords": [], "translations": [ { "language": "en", "title": "Heparin-Induced Thrombocytopenia: Case Report", "abstract": "Heparin-induced thrombocytopenia (HIT) is a catastrophic, rare complication characterized by arterial and venous thromboembolism that develops via immunological mechanisms following heparin use. It usually develops 5-14 days after heparin administration. When HIT develops, heparin treatment should be discontinued and direct thrombin inhibitors should be initiated. In this article, we aim to raise awareness of this rare complication by presenting a case of thromboembolic complications that developed due to HIT.", "keywords": [ "heparin, trombositopeni,tromboemboli" ] } ], "subjects": [], "subject_names": [], "published_date": "2019-12-23", "published_year": "2019", "received_date": null, "accepted_date": null, "volume": "12", "issue": null, "page_first": "115", "page_last": "117", "article_number": null, "conference": { "short_name": "ISAS WINTER-2019 (HSS)", "full_title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences", "name": "4th International Symposium on Innovative Approaches in Health and Sports Sciences", "acronym": "ISAS WINTER-2019 (HSS)", "location": "Samsun, Türkiye", "start_date": "2019-11-22", "end_date": null, "public_id": "76ee0eb0-7f71-420c-9d1c-2b81a3a76e96" }, "proceedings": { "title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences", "series_title": "SETSCI Conference Proceedings", "publisher": "SET Technology", "isbn": "978-605-81988-9-0", "eisbn": null, "issn": null, "eissn": "2687-5527", "doi": null, "doi_prefix": "10.36287", "slug": "setsci-volume-12-2019-legacy-87", "public_id": "083b6600-6489-43ad-9a7d-d9fd7505e910", "url": "https://www.set-science.com/p/setsci-volume-12-2019-legacy-87" }, "license": { "name": "CC BY 4.0", "url": "https://creativecommons.org/licenses/by/4.0/", "code": "CC-BY-4.0", "open_access": true }, "copyright": { "holder": "SET Technology", "year": "2019" }, "funding_statement": null, "funders": [], "references": [ { "order": 1, "raw": "1.\tFranchini M. Heparin-induced thrombocytopenia: an update. Thrombosis Journal 2005; 3: 14. \r\n2.\tWarkentin TE, Grienacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311-37. \r\n3.\tPappalardo F, Crescenzi G, Franco A, Zangrillo A. Early heparin-induced thrombocytopaenia (HIT) after cardiac surgery. Eur J Anaesthesiol 2006;23:806-8.\r\n4.\tWarkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians Chest. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):340S-380S\r\n5.\tKuo KH, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology, 10(4): 271-5, 2005. 8. Francis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 11(30): 3931-41, 2005.\r\n6.\tFrancis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 11(30): 3931-41, 2005\r\n7.\tOtis SA and Zehnder JL. Heparin-induced thrombocytopenia: Current status and diagnostic challenges. Am J Hematol 2010; 85:700–706.\r\n8.\tRefaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin- induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 119: 497-504, 2003.\r\n", "doi": null, "title": null, "authors": null, "source": null, "year": null, "volume": null, "pages": null } ], "statements": { "acknowledgements": null, "conflict_of_interest": null, "data_availability": null, "ai_disclosure": null }, "credit": [], "history": { "published": "2019-12-23" } }